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The three-paper series on guidance for
evidence-informed decisions about health
systems, published in PLoS Medicine, and
produced by members of the World
Health Organization (WHO) Task Force
on Developing Health Systems Guidance,
offers important contributions to improv-
ing the quality of evidence-informed
decision-making in health systems [1–3].
We recognize the importance of engen-
dering greater structure and systematiza-
tion in processes that collate and evaluate
evidence, and bring it to bear on policy.
However, there are significant challenges
in doing this for policies related to health
systems, and we caution against the
adoption of rigid approaches to the
development of guidance and to the appli-
cation of evidence to policy.
In recognizing the growing interna-
tional consensus on the importance of
strengthening health systems, particularly
in low- and middle-income-countries
(LMICs), the first paper argues that better
guidance is needed to provide evidence-
informed decisions about interventions in
health systems, analogous to the methods
that have been used to develop clinical
guidelines, and facilitate their implemen-
tation [1]. The second paper seeks to
identify a series of practical processes and
tools for policy development at interna-
tional and national levels, and for devel-
oping guidance at the national level [2].
Many of the same authors have developed
the Supporting Policy Relevant Trials
(SUPPORT) tools [6] that provide a basis
for a very systematic approach to organiz-
ing questions about health systems prob-
lems and decisions influenced by evidence
(Tables 1–3 in [2]). The third paper at-
tempts to adapt guidelines used in clinical
evidence-based medicine to understand
the quality of health systems evidence
using the Grading of Recommendations
Assessment, Development and Evaluation
(GRADE) criteria [3,7].
In the first paper, Xavier Bosch-Cap-
blanch et al. identify multiple uses of
guidance on health systems from a review
of national policies and plans in LMICs,
but for some of the guidance identified—
such as the operational guidelines for pro-
curement, human resource management,
or planning and budgeting procedures—
one wonders whether research evidence is
critical. The authors offer little guidance as
to where health systems guidance is most
needed. Given the fairly resource-intensive
approach proposed to producing health
systems guidance a clear sense of priorities
is required, and a recognition that some-
times adherence to ‘‘best practice’’ may be
sufficient.
The papers pay relatively little attention
to the well known ‘‘policy-implementation
gap’’, and sometimes appear to presume
that getting policy right is sufficient. The
WHO essential medicines program has
encountered significant success in promot-
ing the widespread adoption of an extensive
set of guidelines (at global, national, and
local levels) related to the development of
evidence-based policies, institutions, and
procedures [4]. Over 150 countries have
adopted essential medicines lists based on
thoughtful and evidence-informed guidance
[5]. Yet, despite this significant success,
policy implementation of essential medi-
cines programs continues to face enormous
challenges, with widespread irrational med-
icines use and a growing threat of counter-
feit medicines. In practice, policy develop-
ment israrelya one-timeevent,but israther
a continuous process. National-level poli-
cy decisions may provide the overarching
framework for change, but commonly the
details of policy change are worked out on
the ground through implementation pro-
cesses and reflected in more informal
expressions of policy such as ministerial
memos and training manuals. While the
second paper [2] in the series, by John Lavis
et al., portrays a relatively clean process of
interaction between global guidance and
national guidance and policy, in prac-
tice there are likely to be multiple policy
iterations as problems and issues merge.
Accordingly, while establishing structured
processes to promote evidence use, we must
not lose sight of the importance of building
networks of researchers and policy makers
to facilitate ongoing dynamic interaction.
The authors of the third paper, Simon
Lewin et al., note that systematic evidence
is needed to address questions of feasibi-
lity and acceptability of interventions, as
well as effectiveness, though much of the
discussion in the paper addresses evidence
regarding ‘‘what can work’’, a question for
which GRADE criteria function well. But
policy makers may be more interested in
questions such as ‘‘what can work in our
(non-research) environment?’’, ‘‘how can
we make an intervention work well?’’,
or ‘‘how can we overcome obstacles to
implementation in our situation?’’ They
are also likely to be more concerned about
the broader type of unintended conse-
quences of an intervention (e.g., the poli-
tical ramifications) [8], the type of results
that are often not well examined by typi-
cal research on ‘‘what can work’’. These
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makers require different types of evidence
than those that fit GRADE criteria. In
addition, policy makers may have a
different view about whether the type of
inference they need to make is the same as
those that drive scientists’ questions on
intervention effectiveness. They are un-
likely to want to bind policy decisions to
the ironically unscientific conventions of
the health sciences with respect to proba-
bilities of error, particularly when such p-
values have little relevance to the nature of
the policy question involved [9].
One implication of the realization that
health systems, like most social systems,
are actually complex adaptive systems,
means that change often follows counter-
intuitive and more complex patterns than
is modeled through epidemiologic re-
search on effectiveness embodied in the
GRADE approach to evidence [10]. For
example, the claim that a large effect size
implies higher quality of evidence is likely
to be true if health systems are determin-
istic or operate in a state of relative
stochastic equilibrium, though this is often
not the case in reality. In complex systems,
small stimuli can lead to large effect sizes,
and large interventions can lead to small
change, but not in a very predictable way,
particularly if the underlying phenomena
are not well understood. Phenomena such
as path dependency, emergent properties,
and other non-linear patterns that occur in
complex systems are often unmeasured in
studies assessed to be high quality accord-
ing to GRADE criteria, and thus such
studies can lead to inappropriate inferenc-
es based on studies designed to fit GRADE
criteria. Different scientific models may be
necessary to interpret the quality of studies
of complex systems [10]. An important
practical implication is that a misplaced
belief in simplistic systems can lead to poor
policy decisions, frequently with policies
that protect against small or moderate
risks, but not against large-scale failure
[11].
Although the papers together acknowl-
edge that guidance needs to take account
of contextual differences, the fragmented
approach proposed to assess evidence on
(i) effects, (ii) stakeholder views, and (iii)
implementation issues suggests that the
implications of context may not have been
fully appreciated. From a systems perspec-
tive, stakeholder views, for example, mat-
ter in terms of how the population or other
actors are likely to receive a health systems
intervention proposal, and also fundamen-
tally influence how that reform is im-
plemented and the effects it creates. Actor
resistance may lead to emergent beha-
vior (such as seeking ways to ‘‘game’’ a
provider payment system) that will in
turn influence effectiveness. A better defi-
nition of health systems interventions than
that proposed in this series would high-
light the need for systems sciences and
interdisciplinary inquiry and further ex-
pand the conceptualization of what com-
prises evidence.
Finally, one key assumption behind the
approach to guidance development pro-
posed is that systematic reviews provide
the best type of evidence on the effects of
policy options, but this is contestable. In
the first place, one could argue that the
best evidence is that which is experienced,
learned, and acted on by key stakeholders
in their own setting. While there is very
little evidence about how policy makers
in LMICs understand systematic reviews,
based on our personal experience, we sus-
pect that such understanding is often quite
limited, and literature instead consistently
points to the importance of personal inter-
actions with researchers and locally pro-
duced evidence in the minds of policy
makers. Systematic reviews clearly have an
important place in the consideration of
evidence, but as previously noted, there
are many types of questions about policy
options that are not well addressed by
systematic reviews of effects or GRADE
criteria that are weighted towards simple
effectiveness studies. As the authors imply,
methods for alternative types of reviews
are still under development and continue
to be debated and to some extent con-
tested. Finally, although it is an impor-
tant scientific principle embodied in the
GRADE criteria that experiments need to
be repeated to gain confidence in the
validity of their findings, we also need to
be cautious of the ‘‘fallacy of misplaced
concreteness’’, and particularly the as-
sumption that because actions have been
successful in some contexts, they need be
under all conditions [8,12].
The articles in this series point to a large
agenda to better develop guidance to
incorporate the different types of evidence
needed for interventions in health systems,
and have made a considerable contribu-
tion toward that end. Recognizing the
diversity of stakeholders and complexity of
health systems issues, it will be important
to ensure that evidence-informed guide-
lines that emerge are tested with continued
humility and skepticism, and that they
do not become rigid models for inquiry
dominated by a limited number of disci-
plines. They should not serve to blind us
toward the need to address a wide variety
of questions and incorporate the different
types of evidence brought to bear by many
fields of science. Further guidance is one
important way to shape policy, but we
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context of sustained dialogue between
researchers and policy makers.
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